Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)

NCT01140061 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: MK-0873 Patch
DRUG: MK-0873 Cream
DRUG: Placebo Patch
DRUG: Placebo Cream
DRUG: Plain patch

Sponsor

Merck Sharp & Dohme LLC